{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T18:40:08Z","timestamp":1786992008619,"version":"build-2736575974"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,7,16]],"date-time":"2024-07-16T00:00:00Z","timestamp":1721088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100022606","name":"Almirall SA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jdin.2024.07.001","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T04:44:21Z","timestamp":1721277861000},"page":"6-14","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Safety and tolerability of tirbanibulin ointment 1% treatment on 100\u00a0cm2 of the face or scalp in patients with actinic keratosis: A phase 3 study"],"prefix":"10.1016","volume":"17","author":[{"given":"Neal","family":"Bhatia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Lain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Jarell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"DuBois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luisa","family":"Tamarit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meritxell","family":"Falques","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Kiyasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Padull\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Otero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Blauvelt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jdin.2024.07.001_bib1","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1111\/bjd.14852","article-title":"Current perspective on actinic keratosis: a review","volume":"177","author":"Siegel","year":"2017","journal-title":"Br J Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.jdin.2024.07.001_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/jdv.14151","article-title":"From actinic keratosis to squamous cell carcinoma: pathophysiology revisited","volume":"31","author":"Fernandez Figueras","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jdin.2024.07.001_bib3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/medicina55040092","article-title":"Prevalence, discontinuation rate, and risk factors for severe local site reactions with topical field treatment options for actinic keratosis of the face and scalp","volume":"55","author":"Balcere","year":"2019","journal-title":"Medicina (Kaunas)"},{"issue":"4","key":"10.1016\/j.jdin.2024.07.001_bib4","doi-asserted-by":"crossref","first-page":"e209","DOI":"10.1016\/j.jaad.2021.02.082","article-title":"Guidelines of care for the management of actinic keratosis","volume":"85","author":"Eisen","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2024.07.001_bib5","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.jaad.2022.04.013","article-title":"Focused update: guidelines of care for the management of actinic keratosis","volume":"87","author":"Eisen","year":"2022","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jdin.2024.07.001_bib6","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1001\/jamadermatol.2021.3180","article-title":"Consensus-based recommendations on the prevention of squamous cell carcinoma in solid organ transplant recipients","volume":"157","author":"Massey","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"1","key":"10.1016\/j.jdin.2024.07.001_bib7","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bjd.15107","article-title":"British Association of Dermatologists' guidelines for the care of patients with actinic keratosis 2017","volume":"176","author":"de Berker","year":"2017","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jdin.2024.07.001_bib8","article-title":"Swiss clinical practice guidelines on field cancerization of the skin","volume":"144","author":"Hofbauer","year":"2014","journal-title":"Swiss Med Wkly"},{"issue":"11","key":"10.1016\/j.jdin.2024.07.001_bib9","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1111\/jdv.13180","article-title":"Evidence- and consensus-based (S3) guidelines for the treatment of actinic keratosis - international league of dermatological societies in cooperation with the European Dermatology forum - short version","volume":"29","author":"Werner","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"10","key":"10.1016\/j.jdin.2024.07.001_bib10","first-page":"1249","article-title":"S3 guideline \u201cactinic keratosis and cutaneous squamous cell carcinoma\u201d- update 2023, part 1: treatment of actinic keratosis, actinic cheilitis, cutaneous squamous cell carcinoma in situ (Bowen's disease), occupational disease and structures of care","volume":"21","author":"Heppt","year":"2023","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jdin.2024.07.001_bib11","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.2147\/CCID.S374122","article-title":"Tirbanibulin for actinic keratosis: insights into the mechanism of action","volume":"15","author":"Schlesinger","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"11","key":"10.1016\/j.jdin.2024.07.001_bib12","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1021\/acs.jmedchem.8b00164","article-title":"Discovery of novel dual mechanism of action src signaling and tubulin polymerization inhibitors (KX2-391 and KX2-361)","volume":"61","author":"Smolinski","year":"2018","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.jdin.2024.07.001_bib13","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.36849\/JDD.2020.5576","article-title":"Tirbanibulin ointment 1% as a novel treatment for actinic keratosis: phase 1 and 2 results","volume":"19","author":"Kempers","year":"2020","journal-title":"J Drugs Dermatol"},{"issue":"6","key":"10.1016\/j.jdin.2024.07.001_bib14","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1056\/NEJMoa2024040","article-title":"Phase 3 trials of tirbanibulin ointment for actinic keratosis","volume":"384","author":"Blauvelt","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.jdin.2024.07.001_bib15","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1177\/10600280211031329","article-title":"1% tirbanibulin ointment for the treatment of actinic keratoses","volume":"56","author":"Dao","year":"2022","journal-title":"Ann Pharmacother"},{"issue":"3","key":"10.1016\/j.jdin.2024.07.001_bib16","doi-asserted-by":"crossref","first-page":"771","DOI":"10.25251\/skin.7.3.3","article-title":"Clinician- and patient-reported outcomes with tirbanibulin 1% treatment for actinic keratosis in routine clinical practice across the U.S. (PROAK study)","volume":"7","author":"Schlesinger","year":"2023","journal-title":"J of Skin"},{"issue":"9 Suppl S2-S12","key":"10.1016\/j.jdin.2024.07.001_bib19","first-page":"S2","article-title":"Comprehensive management of actinic keratoses","volume":"7","author":"Del Rosso","year":"2014","journal-title":"J Clin Aesthet Dermatol"},{"issue":"Suppl 2","key":"10.1016\/j.jdin.2024.07.001_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/jdv.14152","article-title":"Treatment considerations in actinic keratosis","volume":"31","author":"Goldenberg","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"10.1016\/j.jdin.2024.07.001_bib21","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/cpdd.1368","article-title":"Pharmacokinetics, safety, and tolerability of a single 5-day treatment of tirbanibulin ointment 1% in 100 cm2: a phase 1 maximal-use trial in patients with actinic keratosis","volume":"13","author":"DuBois","year":"2024","journal-title":"Clin Pharmacol Drug Dev"},{"key":"10.1016\/j.jdin.2024.07.001_bib22","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2147\/CCID.S121323","article-title":"Patient satisfaction and reported outcomes on the management of actinic keratosis","volume":"10","author":"Khanna","year":"2017","journal-title":"Clin Cosmet Investig Dermatol"},{"issue":"7","key":"10.1016\/j.jdin.2024.07.001_bib23","first-page":"43","article-title":"Actinic keratoses: a comprehensive update","volume":"2","author":"Ibrahim","year":"2009","journal-title":"J Clin Aesthet Dermatol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000981?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328724000981?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T15:41:41Z","timestamp":1748533301000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328724000981"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":21,"alternative-id":["S2666328724000981"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2024.07.001","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and tolerability of tirbanibulin ointment 1% treatment on 100\u00a0cm2 of the face or scalp in patients with actinic keratosis: A phase 3 study","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2024.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}